

Treatment-Naïve and Treatment-Experienced

# Daclatasvir + Sofosbuvir in HCV GT 1-4 and HIV Coinfection ALLY-2 Study

Wyles DL, et al. N Engl J Med. 2015;373:714-25.

# Daclatasvir + Sofosbuvir for HCV GT 1-4 and HIV Coinfection


## ALLY-2 Trial: Study Features

### ALLY-2: Features

- **Design:** Phase 3, open-label study of daclatasvir (DCV) plus sofosbuvir (SOF) in treatment-naïve or experienced, chronic HCV GT 1-4 and HIV coinfection
- **Setting:** Multiple centers in the United States
- **Entry Criteria**
  - N = 395 patients enrolled
  - Chronic HCV Genotype 1 through 4
  - Treatment-naïve or treatment experienced
  - Noncirrhotic or compensated cirrhosis (less than 50%)
  - Stable ARV with HIV RNA < 50 copies/ml at screening and <200 copies/ml for ≥8 weeks; and CD4 count > 100 cells/mm<sup>3</sup>
  - ARVs allowed: tenofovir, emtricitabine, abacavir, lamivudine, zidovudine, darunavir-ritonavir, atazanavir-ritonavir, lopinavir-ritonavir, efavirenz, nevirapine, rilpivirine, dolutegravir, raltegravir, enfuvirtide, maraviroc
- **End-Points:** Primary = SVR12

# Daclatasvir + Sofosbuvir for HCV GT 1-4 and HIV Coinfection ALLY-2 Trial: Design

Week 0 8 12 20 24



## Drug Dosing

Daclatasvir: 60 mg once daily; with efavirenz and nevirapine the dose was increased to 90 mg once daily and with ritonavir-boosted protease inhibitors the dose was decreased to 30 mg once daily

Sofosbuvir: 400 mg once daily

# Daclatasvir + Sofosbuvir for HCV GT 1-4 and HIV Coinfection

## ALLY-2 Trial: Patient Characteristics

Characteristic	Treatment-Naïve 12-Week Group (n=101)	Treatment-Naïve 8-Week Group (n=50)	Previously Treated 12-Week Group (n=52)
Male, n (%)	92 (91%)	42 (84%)	43 (83%)
Median age, years (range)	52 (24-71)	51(28-75)	57 (43-66)
Race			
White	66 (65%)	28 (56%)	31 (60%)
Black	30 (30%)	19 (38%)	20 (38%)
Asian/other	5 (5%)	3 (6%)	1 (2%)
HCV genotype			
1A	71 (70%)	35 (70%)	33 (63%)
1B	12 (12%)	6 (12%)	11 (21%)
2	11 (11%)	6 (12%)	2 (4%)
3	6 (6%)	3 (6%)	4 (8%)
4	1 (1%)	0	2 (4%)
Cirrhosis	9 (9%)	5 (10%)	15 (29%)
Median HCV RNA log <sub>10</sub> (IU/mL)(range)	6.7 (3.3-7.6)	6.4 (4.2-7.5)	6.7 (3.9-7.9)

Source: Wyles DL, et al. N Engl J Med. 2015;373:714-25.

# Daclatasvir + Sofosbuvir for HCV GT 1-4 and HIV Coinfection


## ALLY-2 Trial: HIV Characteristics

Characteristic	Treatment-Naïve 12-Week Group (n=101)	Treatment-Naïve 8-Week Group (n=50)	Previously Treated 12-Week Group (n=52)
Median CD4 count (range)— cells/mm <sup>3</sup>	520 (122-1147)	575 (157-1430)	636 (262-1470)
HIV-1 RNA <50 copies/ml	94/100 (94%)	45/48 (94%)	47/49 (96%)
Antiretroviral treatment, %	Total 99%	Total 96%	Total 98%
Darunavir-ritonavir	19%	44%	22%
Atazanavir-ritonavir	19%	10%	24%
Lopinavir-ritonavir	9%	6%	0
Efavirenz	18%	17%	16%
Nevirapine	5%	2%	6%
Rilpivirine	5%	2%	2%
Raltegravir	22%	17%	20%
Dolutegravir	3%	2%	8%
Nucleoside RTI only	0	0	4%

Source: Wyles DL, et al. N Engl J Med. 2015;373:714-25.

# Daclatasvir + Sofosbuvir for HCV GT 1-4 and HIV Coinfection ALLY-2 Trial: Results for Genotype 1

## SVR12, Genotype 1




Abbreviations: DCV = daclatasvir; SOF = sofosbuvir

Source: Wyles DL, et al. *N Engl J Med.* 2015;373:714-25.

# Daclatasvir + Sofosbuvir for HCV GT 1-4 and HIV Coinfection ALLY-2 Trial: Results

## SVR12, Genotype 1 and subtypes




n=11 had missing or inconclusive findings for cirrhosis & not included in denominators

Source: Wyles DL, et al. N Engl J Med. 2015;373:714-25.

# Daclatasvir + Sofosbuvir for HCV GT 1-4 and HIV Coinfection ALLY-2 Trial: Results for Genotype 1

## SVR12, Genotype 1, by Liver Status




Abbreviations: DCV = daclatasvir; SOF = sofosbuvir

Source: Wyles DL, et al. N Engl J Med. 2015;373:714-25.

# Daclatasvir + Sofosbuvir for HCV GT 1-4 and HIV Coinfection ALLY-2 Trial: Results for Genotype 2

## SVR12, Genotype 2




Abbreviations: DCV = daclatasvir; SOF = sofosbuvir

Source: Wyles DL, et al. N Engl J Med. 2015;373:714-25.

# Daclatasvir + Sofosbuvir for HCV GT 1-4 and HIV Coinfection ALLY-2 Trial: Results for Genotype 3

## SVR12, Genotype 3




Abbreviations: DCV = daclatasvir; SOF = sofosbuvir

Source: Wyles DL, et al. *N Engl J Med.* 2015;373:714-25.

# Daclatasvir + Sofosbuvir for HCV GT 1-4 and HIV Coinfection ALLY-2 Trial: Results for Genotype 4

## SVR12, Genotype 4



Abbreviations: DCV = daclatasvir; SOF = sofosbuvir

Source: Wyles DL, et al. N Engl J Med. 2015;373:714-25.

# Daclatasvir + Sofosbuvir for HCV GT 1-4 and HIV Coinfection ALLY-2 Trial: Conclusion

**Conclusion:** “Among previously untreated HIV–HCV coinfecting patients receiving daclatasvir plus sofosbuvir for HCV infection, the rate of sustained virologic response across all genotypes was 97.0% after 12 weeks of treatment and 76.0% after 8 weeks.”

This slide deck is from the University of Washington's *Hepatitis C Online* and *Hepatitis Web Study* projects.

Hepatitis C Online

[www.hepatitisc.uw.edu](http://www.hepatitisc.uw.edu)

Hepatitis Web Study

<http://depts.washington.edu/hepstudy/>

Funded by a grant from the Centers for Disease Control and Prevention.